are associated with differences in pathophysiological background (7). 
Methods

Patients
Clinical phenotyping
Clinical data was collected from all IPH and CVID patients to annotate their clinical 
Flow cytometric analysis and assignment of B-cell patterns
Six-color flow cytometric immunophenotyping of peripheral blood was performed on a CantoII (BD Biosiences) and data were analyzed using FACS Diva software (BD Biosiences). defined as a value below the 5 th or above the 95 th percentile. B-cell patterns were determined as described previously (7) and are summarized together with their pathophysiological background in Table 1 .
Statistics
Statistical analysis was performed with Graphpad prism 5.0 software (Graphpad Software, San Diego, CA, USA). Whenever two groups with continuous outcomes were compared the Mann Whitney test was applied. Whenever multiple groups with continuous outcomes were compared the non-parametric Kruskal-Wallis rank sum test was used, followed by pair-wise Mann Whitney tests if the former indicated significant differences. For categorical variables the chi-square was used or Fisher's exact test if required. Statistical significance was set at two sided P<0.05.
Results
Patient characteristics
In this study, 44 CVID patients were included, with a mean age of 32 years (range 6-77 years)
and 21 patients with IPH with a mean age 27 years (range 4-74). The age and sex distribution was comparable between both groups. In the CVID group, 2/44 patients were from consanguineous families and in 10/44 patients the family history was positive for hypogammaglobulinemia and/or IgA deficiency, compared to 1/21 and 6/21 in IPH, respectively.
Details regarding immunoglobulin levels, response to immunization and infectious
clinical complications of IPH patients are provided in Table 2 . All IPH patients displayed reduced serum IgG levels, but did not fulfill the diagnostic criteria for CVID due to: adequate response to immunization (7 patients), normal levels of IgA and IgM (3 patients) or both (7 patients) ( Table 2) . Four patients had normal levels of both IgA and IgM (Table 2 ; patient 15-18), but vaccination data were not available. The median IgG levels at diagnosis were lower in patients with CVID (3.0 g/L, range 0-5.7) compared to IPH (4.9 g/L, range 3.6-6.6) ( Figure   1A ). Considering the IgG subclass levels, most patients had IgG1 levels just below the normal range, with IgG2, IgG3 and IgG4 levels in the (lower) normal range (Table 1) . In six patients
IgG subclasses were in the (lower) normal range in the presence of a decreased total IgG. In addition, IgM and IgA levels were lower in CVID, which was an expected finding because of the clinical definition of CVID and IPH.
Clinical phenotypes in CVID and IPH
All patients with CVID and IPH suffered from recurrent upper respiratory tract infections. For IPH, the infectious complications are summarized in Table 2 . Many IPH patients suffer from severe pneumonia (one ore more episodes with hospital admission) and bronchiectasis. These complications were present in a similar frequency compared to CVID patients (50% versus 48% and 24% versus 27%, respectively).
Specific non-infectious disease-related clinical phenotypes (auto-immune cytopenia, polyclonal lymphocytic proliferation and persistent unexplained enteropathy) are associated with an increased mortality in patients with CVID (2-3). In our cohort, 79% of the CVID patients suffered from infections only, with the remaining 21% experiencing one ore more disease-related non-infectious clinical complications ( Figure 1B) . In contrast, all IPH patients suffered only from infections. Therefore, non-infectious disease related complications were exclusively observed in CVID (P=0.02).
Treatment
All CVID patients were treated with immunoglobulin replacement therapy. Of the IPH patients, 12/21 (57%) received immunoglobulin replacement (sometimes in combination with prophylactic antibiotics). Of the remaining nine patients, three were treated with prophylactic antibiotics and six received antibiotics during infectious episodes as the only mode of treatment.
B-cell subsets in healthy controls
In order to detect abnormalities in peripheral B-cell subset distribution in patients, we generated age related normal values of all B-cell subsets in a cohort of 130 healthy controls ( 
Memory B-cell subsets are more severely affected in CVID than in IPH patients
Data of memory B-cells subsets of CVID and IPH patients were compared to age-matched controls and the proportion of patients with normal (>5 th percentile of age matched normal controls) and reduced (<5 th percentile) memory B-cell subset size was determined cut of values are summarized in Table 3 ). The results are depicted in Figure 4 . The T-cell independent CD27-IgA+ memory B-cell subset was normal in the majority of CVID and IPH patients. In CVID, four memory B-cell subsets were more frequently reduced compared to In line with the clinical differences, analysis of the earlier presented B-cell patterns (7) revealed that defective B-cell production and early peripheral B-cell maturation or survival defect (B-cell pattern 1 and 2, respectively) were exclusively seen in CVID. In addition, we
showed that these two B-cell patterns are associated with non-infectious disease related clinical complications. Early defects in B-cell development apparently tend to result in the full CVID phenotype and more often give rise to immune deregulation. Further analysis of B-cell patterns showed that more than half of the CVID patients displays B-cell pattern 1-3, indicative of defects in peripheral B-cell development before the GC stage. In contrast, the majority of IPH patients did not show abnormalities in peripheral B-cell distribution, suggesting a defect in post-GC (terminal) B-cell or a plasma cell defect such as a differentiation, a survival and/or homing defect. Thus, the identification of B-cell patterns is useful to detect differences in pathophysiological background and has the potential to become clinically relevant in the follow up of CVID and IPH, because of the association with noninfectious clinical complications.
We analyzed memory B-cell subsets in CVID and IPH and compared these to 130 age matched controls. We showed that absolute numbers of memory B-cell subsets in healthy individuals reach adult levels within 2 years of age and do not substantially increase Table 1 ). &IgG subclasses were sometimes performed at a different time points than IgG, IgA and IgM levels. **response to pneumococcal polysaccharides was interpreted according to Borgers et al. (8) . $ all patients experienced recurrent upper respiratory tract infections. ENT; frequent and serious Ear Nose and Throat infections (all these patients got multiple ENT operations) Asthma; asthmatic bronchitis, COPD; chronic obstructive pulmonary disease ND; not determined Table 3 . Reference values of peripheral B-cell subset absolute counts. 
